Flemming Ornskov is a Swiss businessperson who has been at the head of 14 different companies.
He holds the position of Non-Executive Chairman of Astion Pharma A, Chairman-Supervisory Board at Centogene NV, Non-Executive Chairman-Supervisory Board at Centogene AG, Chief Executive Officer at Shire Pharmaceuticals Ltd., Chief Executive Officer of Galderma Pharma SA and President of Bayer HealthCare AG. Flemming Ornskov is also on the board of 5 other companies.
In his past career he was Chairman, President & Chief Executive Officer for Life Cycle Pharma A, Vice Chairman of Evotec SE and Non-Executive Chairman for Evotec International GmbH (a subsidiary of Evotec SE), President & Chief Executive Officer of Veloxis Pharmaceuticals A, President-Global Ophthalmics Business Unit at Novartis AG, Non-Executive Chairman of Recordati SpA, Non-Executive Chairman at Roche Innovation Center Copenhagen A, President & Chief Executive Officer at Ikaria, Inc., Chief Executive Officer & Non-Executive Director at Shire Plc, Principal at Merck & Co., Inc., Analyst-Healthcare Equities at Credit Suisse Securities (Europe) Ltd., Global President-Pharmaceuticals & OTC Division at Bausch + Lomb, Inc., Head-General Medicine Global Business Unit at Bayer Pharma AG and Member of Dolder AG.
Dr. Ornskov received a doctorate from the University of Copenhagen, a graduate degree from Harvard University and an MBA from INSEAD.